Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 1.59
QDEL's Cash to Debt is ranked lower than
61% of the 174 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.52 vs. QDEL: 1.59 )
Ranked among companies with meaningful Cash to Debt only.
QDEL' s 10-Year Cash to Debt Range
Min: 0.09   Max: 13.76
Current: 1.59

0.09
13.76
Equity to Asset 0.55
QDEL's Equity to Asset is ranked lower than
58% of the 161 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.61 vs. QDEL: 0.55 )
Ranked among companies with meaningful Equity to Asset only.
QDEL' s 10-Year Equity to Asset Range
Min: 0.52   Max: 0.88
Current: 0.55

0.52
0.88
F-Score: 6
Z-Score: 3.35
M-Score: -3.97
WACC vs ROIC
8.11%
0.66%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 0.76
QDEL's Operating margin (%) is ranked higher than
52% of the 168 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.30 vs. QDEL: 0.76 )
Ranked among companies with meaningful Operating margin (%) only.
QDEL' s 10-Year Operating margin (%) Range
Min: -13.49   Max: 31.99
Current: 0.76

-13.49
31.99
Net-margin (%) -0.80
QDEL's Net-margin (%) is ranked lower than
51% of the 168 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.43 vs. QDEL: -0.80 )
Ranked among companies with meaningful Net-margin (%) only.
QDEL' s 10-Year Net-margin (%) Range
Min: -10.03   Max: 21.25
Current: -0.8

-10.03
21.25
ROE (%) -0.68
QDEL's ROE (%) is ranked lower than
51% of the 162 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.60 vs. QDEL: -0.68 )
Ranked among companies with meaningful ROE (%) only.
QDEL' s 10-Year ROE (%) Range
Min: -11.35   Max: 26.77
Current: -0.68

-11.35
26.77
ROA (%) -0.46
QDEL's ROA (%) is ranked higher than
51% of the 175 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.19 vs. QDEL: -0.46 )
Ranked among companies with meaningful ROA (%) only.
QDEL' s 10-Year ROA (%) Range
Min: -8.68   Max: 21.27
Current: -0.46

-8.68
21.27
ROC (Joel Greenblatt) (%) 1.80
QDEL's ROC (Joel Greenblatt) (%) is ranked higher than
52% of the 174 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.66 vs. QDEL: 1.80 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
QDEL' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -33.72   Max: 144.35
Current: 1.8

-33.72
144.35
Revenue Growth (3Y)(%) 3.60
QDEL's Revenue Growth (3Y)(%) is ranked lower than
61% of the 114 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.60 vs. QDEL: 3.60 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
QDEL' s 10-Year Revenue Growth (3Y)(%) Range
Min: -5.1   Max: 20.6
Current: 3.6

-5.1
20.6
EBITDA Growth (3Y)(%) -15.90
QDEL's EBITDA Growth (3Y)(%) is ranked lower than
73% of the 101 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.30 vs. QDEL: -15.90 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
QDEL' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -58.2   Max: 242
Current: -15.9

-58.2
242
» QDEL's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

QDEL Guru Trades in Q2 2014

Mario Gabelli 601,000 sh (unchged)
Manning & Napier Advisors, Inc Sold Out
» More
Q3 2014

QDEL Guru Trades in Q3 2014

Paul Tudor Jones 200,000 sh (New)
Mario Gabelli 600,000 sh (-0.17%)
» More
Q4 2014

QDEL Guru Trades in Q4 2014

Steven Cohen 417,200 sh (New)
Mario Gabelli 600,000 sh (unchged)
Paul Tudor Jones 152,400 sh (-23.80%)
» More
Q1 2015

QDEL Guru Trades in Q1 2015

Joel Greenblatt 14,247 sh (New)
Mario Gabelli 600,000 sh (unchged)
Paul Tudor Jones Sold Out
Steven Cohen Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with QDEL

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 42.74
QDEL's Forward P/E is ranked lower than
85% of the 62 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 19.34 vs. QDEL: 42.74 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 3.10
QDEL's P/B is ranked lower than
69% of the 142 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.60 vs. QDEL: 3.10 )
Ranked among companies with meaningful P/B only.
QDEL' s 10-Year P/B Range
Min: 1.07   Max: 6.72
Current: 3.1

1.07
6.72
P/S 3.90
QDEL's P/S is ranked lower than
93% of the 147 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.90 vs. QDEL: 3.90 )
Ranked among companies with meaningful P/S only.
QDEL' s 10-Year P/S Range
Min: 1.19   Max: 6.27
Current: 3.9

1.19
6.27
PFCF 22.60
QDEL's PFCF is ranked higher than
50% of the 62 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 22.50 vs. QDEL: 22.60 )
Ranked among companies with meaningful PFCF only.
QDEL' s 10-Year PFCF Range
Min: 5.91   Max: 393
Current: 22.6

5.91
393
POCF 17.06
QDEL's POCF is ranked higher than
61% of the 80 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 19.74 vs. QDEL: 17.06 )
Ranked among companies with meaningful POCF only.
QDEL' s 10-Year POCF Range
Min: 5.35   Max: 481.67
Current: 17.06

5.35
481.67
EV-to-EBIT 445.64
QDEL's EV-to-EBIT is ranked lower than
100% of the 91 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 22.34 vs. QDEL: 445.64 )
Ranked among companies with meaningful EV-to-EBIT only.
QDEL' s 10-Year EV-to-EBIT Range
Min: -201.7   Max: 590.6
Current: 445.64

-201.7
590.6
Shiller P/E 92.40
QDEL's Shiller P/E is ranked lower than
151% of the 55 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. QDEL: 92.40 )
Ranked among companies with meaningful Shiller P/E only.
QDEL' s 10-Year Shiller P/E Range
Min: 22.56   Max: 1297
Current: 92.4

22.56
1297
Current Ratio 7.90
QDEL's Current Ratio is ranked higher than
87% of the 169 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.64 vs. QDEL: 7.90 )
Ranked among companies with meaningful Current Ratio only.
QDEL' s 10-Year Current Ratio Range
Min: 1.64   Max: 8.08
Current: 7.9

1.64
8.08
Quick Ratio 7.26
QDEL's Quick Ratio is ranked higher than
86% of the 169 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.30 vs. QDEL: 7.26 )
Ranked among companies with meaningful Quick Ratio only.
QDEL' s 10-Year Quick Ratio Range
Min: 1.12   Max: 7.26
Current: 7.26

1.12
7.26
Days Inventory 116.42
QDEL's Days Inventory is ranked lower than
71% of the 135 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 72.34 vs. QDEL: 116.42 )
Ranked among companies with meaningful Days Inventory only.
QDEL' s 10-Year Days Inventory Range
Min: 70.68   Max: 128.92
Current: 116.42

70.68
128.92
Days Sales Outstanding 34.56
QDEL's Days Sales Outstanding is ranked higher than
85% of the 150 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 64.52 vs. QDEL: 34.56 )
Ranked among companies with meaningful Days Sales Outstanding only.
QDEL' s 10-Year Days Sales Outstanding Range
Min: 21.59   Max: 95.31
Current: 34.56

21.59
95.31

Valuation & Return

vs
industry
vs
history
Price/Net Cash 31.10
QDEL's Price/Net Cash is ranked lower than
126% of the 65 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. QDEL: 31.10 )
Ranked among companies with meaningful Price/Net Cash only.
QDEL' s 10-Year Price/Net Cash Range
Min: 7.53   Max: 189.2
Current: 31.1

7.53
189.2
Price/Net Current Asset Value 15.70
QDEL's Price/Net Current Asset Value is ranked lower than
106% of the 83 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. QDEL: 15.70 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
QDEL' s 10-Year Price/Net Current Asset Value Range
Min: 3.45   Max: 272.83
Current: 15.7

3.45
272.83
Price/Tangible Book 6.10
QDEL's Price/Tangible Book is ranked lower than
78% of the 138 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.80 vs. QDEL: 6.10 )
Ranked among companies with meaningful Price/Tangible Book only.
QDEL' s 10-Year Price/Tangible Book Range
Min: 1.14   Max: 15.44
Current: 6.1

1.14
15.44
Price/DCF (Projected) 2.10
QDEL's Price/DCF (Projected) is ranked lower than
87% of the 67 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.60 vs. QDEL: 2.10 )
Ranked among companies with meaningful Price/DCF (Projected) only.
QDEL' s 10-Year Price/DCF (Projected) Range
Min: 0.98   Max: 11.48
Current: 2.1

0.98
11.48
Price/Median PS Value 1.00
QDEL's Price/Median PS Value is ranked higher than
56% of the 146 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.00 vs. QDEL: 1.00 )
Ranked among companies with meaningful Price/Median PS Value only.
QDEL' s 10-Year Price/Median PS Value Range
Min: 0.26   Max: 1.56
Current: 1

0.26
1.56
Earnings Yield (Greenblatt) 0.20
QDEL's Earnings Yield (Greenblatt) is ranked lower than
60% of the 172 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.20 vs. QDEL: 0.20 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
QDEL' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.2   Max: 17.5
Current: 0.2

0.2
17.5

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, ALR, DGX, LIFE, ENZ » details
Traded in other countries:QL1.Germany,
Quidel Corp was incorporated in the State of Delaware. It commenced operations in 1979. The Company operates in one business segment, which develops, manufactures and markets diagnostic testing solutions for applications mainly in infectious diseases and reproductive and women's health. It sells its products directly to end users and distributors, in each case, for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, universities, retail clinics and wellness screening centers. The Company markets its products in the U.S. through a network of national and regional distributors, and a direct sales force. Its diagnostic testing solutions are designed to provide specialized results that serve a broad range of customers, by addressing varying requirements of ease of use, reduced cost, increased test accuracy and reduced time to result. Internationally, the Company sells and markets mainly in Japan, Europe, and the Middle East through exclusive distributor arrangements. During 2012, the Company continued to invest in several key areas: support for clinical research and expanding its communications through promotional campaigns, peer-reviewed technical publications, professional shows and exhibits, symposia, medical education and support of health economics and outcomes research. In 2012, it had manufacturing operations in San Diego and Santa Clara, California and Athens, Ohio Customers for IVD products are mainly centralized laboratories and physician offices and other decentralized non-institutional settings. Its objective is to build a broader-based diagnostic company, with products in market segments that are growing to realize increased shareholder value. The Company competes with several large pharmaceutical and diversified healthcare companies. The testing, manufacture and commercialization of its products are subjected to regulation by numerous governmental authorities, principally the FDA and corresponding state and foreign regulatory agencies.
» More Articles for QDEL

Headlines

Articles On GuruFocus.com
Quidel Receives FDA Clearance for Its AmpliVue Trichomonas Assay: A Hand-Held Molecular Diagnostic T Mar 17 2015 
Quidel Announces Pricing of $150 Million Convertible Senior Notes Offering Dec 02 2014 
Quidel Receives FDA Clearance for Its Lyra(TM) Molecular PCR Assay for the Detection of Human Parain Oct 15 2014 
Quidel Receives FDA Clearance for Its Lyra(R) Molecular PCR Assay for the Detection of Adenovirus Oct 15 2014 
Quidel to Hold Third Quarter 2014 Financial Results Conference Call on October 21, 2014 Oct 15 2014 
Top Insider Buys Highlight: Quidel Corporation Jul 28 2014 
Weekly CEO Buys Highlight: TDY, KOPN, QDEL, SALM, FCAL Mar 24 2012 
CEO Buys 6/10/11: Quidel Corp. Jun 10 2011 
Quidel Corp. Reports Operating Results (10-Q) Oct 29 2010 
Quidel Corp. Reports Operating Results (10-Q) Jul 30 2010 

More From Other Websites
QUIDEL CORP /DE/ Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year May 06 2015
Cramer: Why markets rallied May 04 2015
QUIDEL CORP /DE/ Financials Apr 30 2015
Quidel to Present at the Bank of America Merrill Lynch 2015 Health Care Conference Apr 29 2015
Quidel to Present at the Bank of America Merrill Lynch 2015 Health Care Conference Apr 29 2015
10-Q for Quidel Corp. Apr 26 2015
QUIDEL CORP /DE/ Files SEC form 10-Q, Quarterly Report Apr 24 2015
Quidel tops 1Q profit forecasts Apr 23 2015
Quidel tops 1Q profit forecasts Apr 23 2015
Quidel Corp Earnings Call scheduled for 5:00 pm ET today Apr 23 2015
Quidel Reports First Quarter 2015 Financial Results Apr 23 2015
QUIDEL CORP /DE/ Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Apr 23 2015
Quidel Reports First Quarter 2015 Financial Results Apr 23 2015
Q1 2015 Quidel Corp Earnings Release - After Market Close Apr 23 2015
Quidel to Hold First Quarter 2015 Financial Results Conference Call on April 23, 2015 Apr 09 2015
Quidel to Hold First Quarter 2015 Financial Results Conference Call on April 23, 2015 Apr 09 2015
Cowen Thinks 3 Life Science Stocks Can Beat Earnings Estimates Apr 09 2015
Quidel Receives FDA Clearance for Its AmpliVue Trichomonas Assay: A Hand-Held Molecular Diagnostic... Mar 17 2015
Quidel Receives FDA Clearance for Its AmpliVue Trichomonas Assay: A Hand-Held Molecular Diagnostic... Mar 17 2015
Quidel to Present at Upcoming Conferences Mar 04 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK